Strategic relevance in global clinical research is not granted. It is earned.
Every sponsor has a line in its portfolio strategy.
Above that line sit the countries and sites trusted with pivotal trials, adaptive designs, first-in-human studies and complex oncology programmes. Below it sits the geographies invited later, often for diversification, access, or recruitment support after the core strategy has already been set.
Africa, in many sponsor strategies, still sits below that line.
That should prompt reflection. But it should also make us precise. The point is not simply to argue that Africa deserves priority because exclusion is unfair. Fairness matters. Representation matters. But in sponsor portfolio meetings, strategic allocation rarely shifts because a region is underrepresented. It shifts when the evidence shows that a region is too scientifically valuable, operationally reliable, and regulatorily credible to ignore.
That is the transition African clinical research now has to make: from participation to priority.
What Sponsors Actually Mean by Strategic
In sponsor language, “strategic” is not a compliment. It is a risk calculation.
A country, network, or site becomes strategic when four conditions appear consistently: reliable enrolment performance across multiple trials; data that withstands scrutiny from regulators and sponsor quality teams; therapeutic-area depth aligned with the sponsor pipeline; and an operating environment predictable enough that every new study does not feel like starting from zero.
A strategic site is not merely a place where patients can be found. It is an execution asset.
It reduces uncertainty. It protects timelines. It strengthens the evidence package. It helps sponsors make better development decisions.
The Path Has Been Walked Before
South Korea offers one of the clearest examples. Industry analysis from Norstella positions South Korea, and Seoul in particular, among the world’s leading clinical trial hubs, supported by strong institutional data systems, site performance, and trial infrastructure (1). KoNECT highlights operational markers sponsors care about, including approximately 30 working days from the Ministry of Food and Drug Safety (MFDS) clinical-trial-application submission to approval and roughly three weeks from Institutional Review Board (IRB) submission to approval (2)
The lesson is not that Africa should copy Korea. The lesson is that sponsors reward systems that are easy to trust and easy to use.
Singapore offers a different but equally important comparator. Cambridge Industrial Innovation Policy notes that Singapore launched its biomedical industry strategy in 2000 and opened Biopolis in 2003 as a purpose-built innovation campus (3). Over time, Singapore combined infrastructure, talent, translational platforms, public-private alignment, and clinical research capacity into a coherent national ecosystem (4).
India’s story is larger and more complex, but also instructive. Invest India has described a maturing clinical trial ecosystem that includes hospital-based trial networks, specialist consortia, and the Indian Clinical Trial and Education Network, supported by regulatory reforms and expanding institutional infrastructure (5). Scale mattered, but scale became strategically valuable when it was organized through standards, networks, and regulatory reform.
The common thread is simple: strategic relevance is built by making the system work, then proving that it works repeatedly.
Africa’s Case Is Not Charity. It Is Science.
Africa’s underrepresentation in clinical research is not a marginal problem.
The Access to Medicine Foundation has noted that Africa remains significantly underrepresented in global clinical trial activity despite carrying a substantial share of the global disease burden and population (6). That gap is not just inequitable. It is scientifically inefficient.
The genomic argument is even stronger. The NIH has highlighted Ambroise Wonkam’s observation that less than 2% of human genomes analyzed so far have been from African people, despite Africa containing more genetic diversity than any other continent (7). Human Molecular Genetics has also warned that African underrepresentation constrains gene discovery, weakens the portability of genomic findings and limits the promise of precision medicine (8).
Put plainly: medicines developed without African data may not fully reflect the populations in which they will ultimately be used.
This is where African leadership matters.
The point is not for African sites to be included as a corrective after the protocol has already been written. The point is for African investigators, regulators, ethics committees, patients, data stewards, and research networks to help shape the scientific questions from the beginning.
What Moves Africa Above the Line?
The first condition is enrollment performance.
Sponsors increasingly look for dashboards, benchmarks, and repeatable operational evidence — not isolated anecdotes. African trial networks need more documented performance data across trials, countries, and therapeutic areas.
The second is quality.
Enrollment without data integrity does not build strategic trust. The sites that become indispensable are the ones that produce auditable, regulator-ready data with low query burdens, strong safety reporting, and consistent protocol adherence.
The third is therapeutic-area depth.
Much of the global pipeline is moving through oncology, metabolic disease, cardiovascular disease, immunology, and neuropsychiatry alongside infectious disease and vaccines. African trial infrastructure must align with where global research and development investment is actually going. The future cannot rely only on legacy assumptions about Africa as primarily an infectious-disease recruitment geography.
The fourth is regulatory predictability.
The African Medicines Agency (AMA), headquartered in Kigali, is an important signal because its mandate is to strengthen national authorities, support reliance and joint regulatory work, and improve access to quality, safe, and efficacious medical products across the continent (9,10).
For sponsors, however, predictability becomes meaningful only when it is experienced operationally through timelines that are clearer, approvals that are more coordinated, and regulatory pathways that can support multi-country development plans.
The fifth is contractability.
This is less glamorous, but it is often where strategy becomes real. Sponsors need clear contracting templates, pre-agreed positions on indemnity, data transfer, intellectual property, sample export, budget terms, and accountability. A strong investigator can still lose a protocol if every start-up process requires bespoke negotiation.
African-Led Leadership Must Be Performance-Led
There is a risk in framing Africa only through underrepresentation.
It can make the continent sound like a beneficiary of global goodwill rather than a producer of indispensable science.
African-led leadership changes that frame.
It says African sites should not wait to be invited into someone else’s strategy. They should build networks that aggregate patient access responsibly. They should generate feasibility intelligence sponsors can trust. They should lead investigator development in priority therapeutic areas. They should set high standards for informed consent, community engagement, and data governance. They should make African data visible, interoperable, and protected.
Leadership also means refusing the false choice between speed and ethics.
Africa’s competitive advantage should not be cheap recruitment or permissive oversight. It should be scientific depth, operational readiness, community trust, and quality that travels across regulators.
This is the position networks such as ACRN can help advance: not a plea for inclusion, but a performance-based proposition.
The proposition is that African sites can contribute capabilities global development increasingly needs: diverse populations, strong disease relevance, emerging regulatory harmonization, and investigators capable of leading, not merely implementing.
The Next Line Will Be Drawn by Evidence
In the next decade, sponsors will continue to ask hard questions.
Which countries can enroll? Which sites generate clean data? Which regulators are predictable? Which networks reduce start-up friction? Which populations add scientific value that cannot easily be replicated elsewhere?
Africa can answer those questions.
But it must answer them with evidence.
Not intention alone.
Not potential alone.
And not moral pressure without operational proof.
The move from participation to priority will happen when African clinical research becomes too reliable to ignore, too scientifically valuable to exclude, and too well-led to be treated as peripheral.
The challenge to sponsors is to stop confusing familiarity with quality.
The challenge to African institutions is to convert capability into proof.
And the challenge to all of us is to reframe the conversation: Africa is not asking for a place above the line. African institutions are building the performance, quality, readiness, and scientific value that increasingly make exclusion harder to justify.
References
- Spotlight on South Korea: Innovation, clinical trials, and market trends shaping 2025. Norstella [Internet]. [cited 2026 May 15]. Available from: https://www.norstella.com/insight/spotlight-south-korea-innovation-clinical-trials-market-trends-shaping-2025/
- KONECT 국가임상시험지원재단 [Internet]. [cited 2026 May 15]. Available from: https://www.konect.or.kr/en/index.do
- Singapore’s biomedical cluster: Lessons from two decades of innovation and manufacturing policy. Cambridge Industrial Innovation Policy [Internet]. [cited 2026 May 15]. Available from: https://www.ciip.group.cam.ac.uk/reports-and-articles/singapores-biomedical-cluster-lessons-from-two-decades-of-innovation-and-manufacturing-policy/
- Biomedical and Pharmaceuticals industry | MOE [Internet]. [cited 2026 May 15]. Available from: https://www.moe.gov.sg/sgis/sponsoring-organisations/industries/biomedical-and-pharmaceuticals
- India’s Clinical Trials Surge: Emerging as Global Innovation P… [Internet]. [cited 2026 May 15]. Available from: https://www.investindia.gov.in/team-india-blogs/indias-clinical-trials-surge-emerging-global-innovation-powerhouse
- Harnessing Africa’s untapped clinical trial potential | Access to Medicine [Internet]. [cited 2026 May 15]. Available from: https://accesstomedicinefoundation.org/insights-resources/access-insights/harnessing-africas-untapped-clinical-trial-potential
- Wonkam A. Sequence three million genomes across Africa. Nature. 2021 Feb;590(7845):209–11. doi:10.1038/d41586-021-00313-7
- Ojewunmi OO, Fatumo S. Driving Global Health equity and precision medicine through African genomic data. Hum Mol Genet. 2025 Apr 30;ddaf025. doi:10.1093/hmg/ddaf025
- Nakkazi E. What the launch of the African Medicines Agency means for drug and health regulation. Nat Afr. 2025 Nov 6. doi:10.1038/d44148-025-00350-8
- African Medicines Agency – Improving access to quality, safe and efficacious medical products for the continent. [Internet]. [cited 2026 Apr 29]. Available from: https://au-ama.africa/